The raw feed
Latest filings
Every transaction from every Form 4, as filed, newest first. Open-market buys (P) and sells (S) become signals; the rest is shown for completeness.
| Date | Company | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Goldman Sachs Group Inc other | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -4,445,275 | $0.00 | $0 | 0 | Aug 13, 2026 |
| Aug 11, 2026 | PINS PINTEREST, INC. | Benjamin Silbermann Executive Chairman, Co-F | CConversion Class A Common Stockindirect: Benjamin and Divya Silbermann Family Trust10b5-1 | +46,875 | $0.00 | $0 | 46,875 | Aug 12, 2026 |
| Aug 12, 2026 | PINS PINTEREST, INC. | Benjamin Silbermann Executive Chairman, Co-F | CConversion Class A Common Stockindirect: Benjamin and Divya Silbermann Family Trust10b5-1 | +46,875 | $0.00 | $0 | 46,875 | Aug 12, 2026 |
| Aug 11, 2026 | PINS PINTEREST, INC. | Benjamin Silbermann Executive Chairman, Co-F | CConversion Class B Common Stockderivativeindirect: Benjamin and Divya Silbermann Family Trust10b5-1 | -46,875 | $0.00 | $0 | 34,940,013 | Aug 12, 2026 |
| Aug 12, 2026 | PINS PINTEREST, INC. | Benjamin Silbermann Executive Chairman, Co-F | CConversion Class B Common Stockderivativeindirect: Benjamin and Divya Silbermann Family Trust10b5-1 | -46,875 | $0.00 | $0 | 34,893,138 | Aug 12, 2026 |
| Aug 10, 2026 | CRWV CoreWeave, Inc. | Brannin McBee Chief Development Officer | CConversion Class A Common Stockindirect: Canis Major 2025 GRAT10b5-1 | +40,000 | - | - | 40,000 | Aug 12, 2026 |
| Aug 10, 2026 | CRWV CoreWeave, Inc. | Brannin McBee Chief Development Officer | CConversion Class A Common Stockindirect: Canis Minor 2025 GRAT10b5-1 | +12,500 | - | - | 12,500 | Aug 12, 2026 |
| Aug 10, 2026 | CRWV CoreWeave, Inc. | Brannin McBee Chief Development Officer | CConversion Class B Common Stockderivativeindirect: Canis Major 2025 GRAT10b5-1 | -40,000 | - | - | 3,517,227 | Aug 12, 2026 |
| Aug 10, 2026 | CRWV CoreWeave, Inc. | Brannin McBee Chief Development Officer | CConversion Class B Common Stockderivativeindirect: Canis Minor 2025 GRAT10b5-1 | -12,500 | - | - | 436,205 | Aug 12, 2026 |
| Aug 10, 2026 | CRWV CoreWeave, Inc. | Brannin McBee Chief Development Officer | CConversion Class A Common Stock10b5-1 | +144,000 | - | - | 467,263 | Aug 12, 2026 |
| Aug 10, 2026 | CRWV CoreWeave, Inc. | Brannin McBee Chief Development Officer | CConversion Class A Common Stockindirect: By Spouse10b5-1 | +25,000 | - | - | 25,000 | Aug 12, 2026 |
| Aug 10, 2026 | CRWV CoreWeave, Inc. | Brannin McBee Chief Development Officer | CConversion Class A Common Stockindirect: Brannin J McBee 2022 Irrevocable Trust10b5-1 | +25,000 | - | - | 25,000 | Aug 12, 2026 |
| Aug 10, 2026 | CRWV CoreWeave, Inc. | Brannin McBee Chief Development Officer | CConversion Class A Common Stockindirect: Canis Major 2024 Irrevocable Trust LLC10b5-1 | +3,000 | - | - | 3,000 | Aug 12, 2026 |
| Aug 10, 2026 | CRWV CoreWeave, Inc. | Brannin McBee Chief Development Officer | CConversion Class B Common Stockderivative10b5-1 | -144,000 | - | - | 5,610,894 | Aug 12, 2026 |
| Aug 10, 2026 | CRWV CoreWeave, Inc. | Brannin McBee Chief Development Officer | CConversion Class B Common Stockderivativeindirect: By Spouse10b5-1 | -25,000 | - | - | 1,830,300 | Aug 12, 2026 |
| Aug 10, 2026 | CRWV CoreWeave, Inc. | Brannin McBee Chief Development Officer | CConversion Class B Common Stockderivativeindirect: Brannin J. McBee 2022 Irrevocable Trust10b5-1 | -25,000 | - | - | 3,391,020 | Aug 12, 2026 |
| Aug 10, 2026 | CRWV CoreWeave, Inc. | Brannin McBee Chief Development Officer | CConversion Class B Common Stockderivativeindirect: Canis Major 2024 Irrevocable Trust LLC10b5-1 | -3,000 | - | - | 294,000 | Aug 12, 2026 |
| Aug 10, 2026 | DDOG Datadog, Inc. | Alexis Le-Quoc Chief Technology Officer | CConversion Class A Common Stock10b5-1 | +43,224 | $0.00 | $0 | 553,029 | Aug 12, 2026 |
| Aug 10, 2026 | DDOG Datadog, Inc. | Alexis Le-Quoc Chief Technology Officer | CConversion Class A Common Stock10b5-1 | +10,688 | $0.00 | $0 | 563,717 | Aug 12, 2026 |
| Aug 10, 2026 | DDOG Datadog, Inc. | Alexis Le-Quoc Chief Technology Officer | CConversion Class B Common Stockderivative10b5-1 | -53,912 | $0.00 | $0 | 2,281,640 | Aug 12, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | 5AM Ventures VI, L.P. owner | CConversion Common Stockindirect: By 5AM Ventures VI, L.P. | +4,975,543 | - | - | 4,975,543 | Aug 12, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | 5AM Ventures VI, L.P. owner | CConversion Common Stockindirect: By 5AM Opportunities II, L.P. | +2,350,419 | - | - | 2,350,419 | Aug 12, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | 5AM Ventures VI, L.P. owner | CConversion Series A Preferred Stockderivativeindirect: By 5AM Ventures VI, L.P. | -3,152,305 | $0.00 | $0 | 0 | Aug 12, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | 5AM Ventures VI, L.P. owner | CConversion Series A-2 Preferred Stockderivativeindirect: By 5AM Ventures VI, L.P. | -1,823,238 | $0.00 | $0 | 0 | Aug 12, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | 5AM Ventures VI, L.P. owner | CConversion Series A-2 Preferred Stockderivativeindirect: By 5AM Opportunities II, L.P. | -866,018 | $0.00 | $0 | 0 | Aug 12, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | 5AM Ventures VI, L.P. owner | CConversion Series B Preferred Stockderivativeindirect: By 5AM Opportunities II, L.P. | -1,484,401 | $0.00 | $0 | 0 | Aug 12, 2026 |
| Aug 10, 2026 | BRLT Brilliant Earth Group, Inc. | Mainsail Gp Iii, LLC owner | CConversion Class B Common Stockindirect: See footnotes | -50,000 | - | - | 31,848,071 | Aug 12, 2026 |
| Aug 10, 2026 | BRLT Brilliant Earth Group, Inc. | Mainsail Gp Iii, LLC owner | CConversion Class A Common Stockindirect: See footnote | +50,000 | - | - | 50,000 | Aug 12, 2026 |
| Aug 10, 2026 | BRLT Brilliant Earth Group, Inc. | Mainsail Gp Iii, LLC owner | CConversion LLC Unitsderivativeindirect: See footnotes | -50,000 | - | - | 31,848,071 | Aug 12, 2026 |
| Aug 10, 2026 | BRLT Brilliant Earth Group, Inc. | Gavin Turner director, owner | CConversion Class B Common Stockindirect: See footnotes | -50,000 | - | - | 31,848,071 | Aug 12, 2026 |
| Aug 10, 2026 | BRLT Brilliant Earth Group, Inc. | Gavin Turner director, owner | CConversion Class A Common Stockindirect: See footnote | +50,000 | - | - | 50,000 | Aug 12, 2026 |
| Aug 10, 2026 | BRLT Brilliant Earth Group, Inc. | Gavin Turner director, owner | CConversion LLC Unitsderivativeindirect: See footnotes | -50,000 | - | - | 31,848,071 | Aug 12, 2026 |
| Aug 7, 2026 | TBBB BBB FOODS INC | Kamal Anthony Hatoum Chairman & CEO | CConversion Class A Common Sharesindirect: By Bolton Partners Ltd. | +16,003,914 | - | - | 16,003,914 | Aug 12, 2026 |
| Aug 7, 2026 | TBBB BBB FOODS INC | Kamal Anthony Hatoum Chairman & CEO | CConversion Class C Common Sharesderivativeindirect: By Bolton Partners Ltd. | -16,003,914 | - | - | 0 | Aug 12, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Sanofi owner | CConversion Common Stockindirect: See footnote | +494,800 | - | - | 494,800 | Aug 12, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Sanofi owner | CConversion Common Stockindirect: See footnote | +177,978 | - | - | 672,788 | Aug 12, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Sanofi owner | CConversion Series B Preferred Stockderivativeindirect: See footnote | -494,800 | - | - | 0 | Aug 12, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Sanofi owner | CConversion Convertible Promissory Notederivativeindirect: See footnote | -177,978 | - | - | 0 | Aug 12, 2026 |
| Aug 10, 2026 | QSR Restaurant Brands International Inc. | 3G Restaurant Brands Holdings General Partner Ltd. owner | CConversion Exchangeable Unitsderivativeindirect: See Footnotes | +2,784,549 | - | - | 96,373,353 | Aug 12, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Carl L Gordon director | CConversion Common Stockindirect: See footnotes | +1,039,996 | - | - | 1,039,996 | Aug 12, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Carl L Gordon director | CConversion Common Stockindirect: See footnotes | +1,049,283 | - | - | 2,089,279 | Aug 12, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Carl L Gordon director | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -1,039,996 | $0.00 | $0 | 0 | Aug 12, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Carl L Gordon director | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,049,283 | $0.00 | $0 | 0 | Aug 12, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Orbimed Advisors LLC director | CConversion Common Stockindirect: See footnotes | +1,039,996 | - | - | 1,039,996 | Aug 12, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Orbimed Advisors LLC director | CConversion Common Stockindirect: See footnotes | +1,049,283 | - | - | 2,089,279 | Aug 12, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Orbimed Advisors LLC director | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -1,039,996 | $0.00 | $0 | 0 | Aug 12, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Orbimed Advisors LLC director | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,049,283 | $0.00 | $0 | 0 | Aug 12, 2026 |
| Aug 7, 2026 | DOCS Doximity, Inc. | Timothy S Cabral director | CConversion Class A Common Stock10b5-1 | +7,500 | - | - | 10,721 | Aug 11, 2026 |
| Aug 7, 2026 | DOCS Doximity, Inc. | Timothy S Cabral director | CConversion Class B Common Stockderivative10b5-1 | -7,500 | $0.00 | $0 | 0 | Aug 11, 2026 |
| Aug 7, 2026 | BRVE Braveheart Bio, Inc. | AH Bio Fund IV, L.P. owner | CConversion Common Stockindirect: By AH Bio Fund IV, L.P. | +9,132,420 | - | - | 9,132,420 | Aug 11, 2026 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.